[{"id":"47dd1b32-326d-4c9b-9c8a-fd5502dd3a1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181788","created_at":"2021-01-18T20:23:26.859Z","updated_at":"2025-02-25T14:07:35.999Z","phase":"Phase 2","brief_title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","source_id_and_acronym":"NCT04181788","lead_sponsor":"Pfizer","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumrad (sasanlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 03/18/2020","start_date":" 03/18/2020","primary_txt":" Primary completion: 03/03/2022","primary_completion_date":" 03/03/2022","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-02-18"},{"id":"28d200e6-3d31-4d3c-b1b7-afb8856e7a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT06704724","created_at":"2025-02-25T16:56:42.270Z","updated_at":"2025-02-25T16:56:42.270Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene","source_id_and_acronym":"NCT06704724","lead_sponsor":"Pfizer","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab) • PF-07284892"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/10/2024","start_date":" 12/10/2024","primary_txt":" Primary completion: 01/30/2028","primary_completion_date":" 01/30/2028","study_txt":" Completion: 01/29/2029","study_completion_date":" 01/29/2029","last_update_posted":"2025-02-04"},{"id":"795a3eed-60a1-4800-a0cc-df6e4a85200a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665361","created_at":"2022-12-27T14:58:35.799Z","updated_at":"2024-07-02T16:34:58.850Z","phase":"Phase 1/2","brief_title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","source_id_and_acronym":"NCT05665361","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Zumrad (sasanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-05"},{"id":"d4b3afea-d3d9-4419-8a44-fcb045a46c84","acronym":"LANDSCAPE 1011","url":"https://clinicaltrials.gov/study/NCT04585815","created_at":"2021-01-18T21:52:42.284Z","updated_at":"2024-07-02T16:35:11.290Z","phase":"Phase 1/2","brief_title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","source_id_and_acronym":"NCT04585815 - LANDSCAPE 1011","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib) • axitinib • Zumrad (sasanlimab) • SEA-TGT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 05/17/2023","primary_completion_date":" 05/17/2023","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-04-05"},{"id":"8abb3331-04ba-4bfa-a734-5fadb9a6b09e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458259","created_at":"2021-08-31T17:53:09.115Z","updated_at":"2024-07-02T16:35:11.509Z","phase":"Phase 1","brief_title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","source_id_and_acronym":"NCT04458259","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Zumrad (sasanlimab) • PF-07265807"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-03"},{"id":"1b165c6f-ea64-459f-b1f5-2f8e3a98fc1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573259","created_at":"2021-01-17T17:43:00.102Z","updated_at":"2024-07-02T16:36:19.570Z","phase":"Phase 1","brief_title":"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors","source_id_and_acronym":"NCT02573259","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • ALK • CD8 • PD-1 • CCR7","pipe":" | ","alterations":" EGFR mutation • ALK mutation • PD-1 positive","tags":["PD-L1 • ALK • CD8 • PD-1 • CCR7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumrad (sasanlimab)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 11/19/2020","study_completion_date":" 11/19/2020","last_update_posted":"2021-12-13"}]